Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

BACKGROUND: The incidence of thyroid cancer and the number of patients who die from this disease are increasing globally. Differentiated thyroid cancer (DTC) is the histologic subtype present in most patients and is primarily responsible for the increased overall incidence of thyroid cancer. Sorafen...

Descripción completa

Detalles Bibliográficos
Autores principales: Brose, Marcia S, Nutting, Christopher M, Sherman, Steven I, Shong, Young Kee, Smit, Johannes WA, Reike, Gerhard, Chung, John, Kalmus, Joachim, Kappeler, Christian, Schlumberger, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164634/
https://www.ncbi.nlm.nih.gov/pubmed/21834960
http://dx.doi.org/10.1186/1471-2407-11-349

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164634/
https://www.ncbi.nlm.nih.gov/pubmed/21834960
http://dx.doi.org/10.1186/1471-2407-11-349

Ejemplares similares